IMPORTANT SAFETY INFORMATION
What is the most important information I should know about KLYGEFA?
KLYGEFA is a medicine that affects your immune system and may lower the ability of your immune system to fight infections.
- You must complete or update meningococcal vaccine(s) at least 2 weeks before your first dose of KLYGEFA.
- If you have not completed your meningococcal vaccines and KLYGEFA must be started right away, you should receive the required vaccine(s) as soon as possible.
- If you have not been vaccinated and KLYGEFA must be started right away, you should also receive antibiotics for as long as your healthcare provider tells you.
- If you had a meningococcal vaccine in the past, you might need additional vaccines before starting KLYGEFA. Your healthcare provider will decide if you need additional meningococcal vaccines.
- Meningococcal vaccines do not prevent all meningococcal infections. Call your healthcare provider or get emergency medical care right away if you get any of these signs and symptoms of a meningococcal infection: fever, fever with high heart rate, headache and fever, confusion, muscle aches with flu-like symptoms, fever and a rash, headache with nausea or vomiting, headache with a stiff neck or stiff back, or eyes sensitive to light.
Your healthcare provider will give you a Patient Safety Card about the risk of serious meningococcal infection. Carry it with you at all times during treatment and for 3 months after your last KLYGEFA dose. Your risk of meningococcal infection may continue for several weeks after your last dose of KLYGEFA. It is important to show this card to any healthcare provider who treats you. This will help them diagnose and treat you quickly.
KLYGEFA is only available through a program called the KLYGEFA Risk Evaluation and Mitigation Strategy (REMS). Before you can receive KLYGEFA, your healthcare provider must: enroll in the REMS program; counsel you about the risk of serious meningococcal infections; give you the Patient Guide, including information about the signs and symptoms of meningococcal infection; give you a Patient Safety Card about your risk of meningococcal infection; make sure that you are vaccinated against serious infections caused by meningococcal bacteria, and that you receive antibiotics if you need to start KLYGEFA right away and are not up to date on your vaccines.
KLYGEFA may also increase the risk of other types of serious infections, including Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria gonorrhoeae. Certain people may be at risk for serious infections with gonorrhea. Call your healthcare provider right away if you have new signs or symptoms of infection.
Do not use KLYGEFA if you have a serious meningococcal infection when you are starting KLYGEFA.
Before you use KLYGEFA, tell your healthcare provider about all of your medical conditions, including if you:
-
have an infection or fever.
-
are pregnant or plan to become pregnant. It is not known if KLYGEFA will harm your unborn baby.
-
are breastfeeding or plan to breastfeed. It is not known if KLYGEFA passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you use KLYGEFA.
Tell your healthcare provider about all the vaccines you receive and medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
The most common side effect of KLYGEFA includes injection site reactions.
These are not all the possible side effects of KLYGEFA. For more information, ask your healthcare provider or pharmacist. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
See the detailed Instructions for Use that comes with KLYGEFA for information on how to prepare and inject a dose of KLYGEFA and how to properly throw away (dispose of) used KLYGEFA autoinjectors. Take KLYGEFA exactly as prescribed by your healthcare provider.
INDICATION
What is KLYGEFA?
KLYGEFA is a prescription medicine used to treat a disease called generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody positive.
It is not known if KLYGEFA is safe and effective in children.
Please see the full Prescribing Information and Medication Guide for KLYGEFA, including Boxed WARNING regarding serious meningococcal infections.